Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate
Jørgensen, Heather G and Allan, Elaine K and Mountford, Joanne C and Richmond, Linda and Harrison, Simon and Elliott, Moira A and Holyoake, Tessa L (2005) Enhanced CML stem cell elimination in vitro by bryostatin priming with imatinib mesylate. Experimental Hematology, 33 (10). pp. 1140-6. ISSN 0301-472X (https://doi.org/10.1016/j.exphem.2005.05.020)
Full text not available in this repository.Request a copyAbstract
In chronic myeloid leukemia (CML), imatinib mesylate (IM; Gleevec, Glivec) induces a G0/G1 cell-cycle block in total CD34(+) cells without causing significant apoptosis. Bryostatin-1 (bryo), a protein kinase C (PKC) modulator, was investigated for its ability to increase IM-mediated apoptosis either through induction of cycling of G0/G1 Ph(+) cells or antagonism of the IM-induced cell-cycle block.
ORCID iDs
Jørgensen, Heather G, Allan, Elaine K, Mountford, Joanne C, Richmond, Linda, Harrison, Simon, Elliott, Moira A
-
-
Item type: Article ID code: 32632 Dates: DateEvent2005PublishedKeywords: antigens, antineoplastic agents, apoptosis, bryostatins, drug antagonism, hematopoietic stem cells, leukemia, macrolides, piperazines, protein kinase C, pyrimidines, Therapeutics. Pharmacology, Neoplasms. Tumors. Oncology (including Cancer), Cell Biology, Genetics, Molecular Biology, Hematology, Cancer Research, SDG 3 - Good Health and Well-being Subjects: Medicine > Therapeutics. Pharmacology
Medicine > Internal medicine > Neoplasms. Tumors. Oncology (including Cancer)Department: Faculty of Science > Strathclyde Institute of Pharmacy and Biomedical Sciences Depositing user: Pure Administrator Date deposited: 19 Aug 2011 20:05 Last modified: 18 Mar 2023 03:40 URI: https://strathprints.strath.ac.uk/id/eprint/32632